Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS).  Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.

Biotechnology

Inhalon

John Whelan

Bill Picht

Brian Farrer

Jeff Hutchins

Thomas Moench

Sam Lai

Scientific Team

Leadership Team

Inhalon

Org chart

Teams

Scientific Team

Leadership Team

Similar companies